Table of Contents Author Guidelines Submit a Manuscript
Clinical and Developmental Immunology
Volume 2011, Article ID 349575, 11 pages
http://dx.doi.org/10.1155/2011/349575
Review Article

Interferon Lambda: A New Sword in Cancer Immunotherapy

1Department of Biochemistry and Molecular Biology, University of Medicine and Dentistry of New Jersey-New Jersey Medical School, University Hospital Cancer Center, 205 South Orange Avenue, Newark, NJ 07103, USA
2Department of Medicine, Division of Medical Oncology, UMDNJ-Robert Wood Johnson Medical School, The Cancer Institute of New Jersey, 195 Little Albany Street, New Brunswick, NJ 08903, USA

Received 1 July 2011; Accepted 16 September 2011

Academic Editor: Graham Ogg

Copyright © 2011 Ahmed Lasfar et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. R. P. Donnelly and S. V. Kotenko, “Interferon-lambda: a new addition to an old family,” Journal of Interferon and Cytokine Research, vol. 30, no. 8, pp. 555–564, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  2. S. V. Kotenko, G. Gallagher, V. V. Baurin et al., “IFN-λs mediate antiviral protection through a distinct class II cytokine receptor complex,” Nature Immunology, vol. 4, no. 1, pp. 69–77, 2003. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  3. P. Sheppard, W. Kindsvogel, W. Xu et al., “IL-28, IL-29 and their class II cytokine receptor IL-28R,” Nature Immunology, vol. 4, no. 1, pp. 63–68, 2003. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  4. A. Lasfar, A. Lewis-Antes, S. V. Smirnov et al., “Characterization of the mouse IFN-λ ligand-receptor system: IFN-λs exhibit antitumor activity against B16 melanoma,” Cancer Research, vol. 66, no. 8, pp. 4468–4477, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  5. N. Ank, M. B. Iversen, C. Bartholdy et al., “An important role for type III interferon (IFN-λ/IL-28) in TLR-induced antiviral activity,” Journal of Immunology, vol. 180, no. 4, pp. 2474–2485, 2008. View at Google Scholar · View at Scopus
  6. N. Ank, H. West, C. Bartholdy, K. Eriksson, A. R. Thomsen, and S. R. Paludan, “Lambda interferon (IFN-λ), a type III IFN, is induced by viruses and IFNs and displays potent antiviral activity against select virus infections in vivo,” Journal of Virology, vol. 80, no. 9, pp. 4501–4509, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  7. D. Kugel, G. Kochs, K. Obojes et al., “Intranasal administration of alpha interferon reduces seasonal influenza A virus morbidity in ferrets,” Journal of Virology, vol. 83, no. 8, pp. 3843–3851, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  8. M. Mordstein, G. Kochs, L. Dumoutier et al., “Interferon-λ contributes to innate immunity of mice against influenza A virus but not against hepatotropic viruses,” PLoS Pathogens, vol. 4, no. 9, Article ID e1000151, 2008. View at Publisher · View at Google Scholar · View at PubMed
  9. M. Li, X. Liu, Y. Zhou, and B. S. Shao, “Interferon-λs: the modulators of antivirus, antitumor, and immune responses,” Journal of Leukocyte Biology, vol. 86, no. 1, pp. 23–32, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  10. G. Uzé and D. Monneron, “IL-28 and IL-29: newcomers to the interferon family,” Biochimie, vol. 89, no. 6-7, pp. 729–734, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  11. S. H. Hong, O. Cho, K. Kim, H. J. Shin, S. V. Kotenko, and S. Park, “Effect of interferon-lambda on replication of hepatitis B virus in human hepatoma cells,” Virus Research, vol. 126, no. 1-2, pp. 245–249, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  12. C. A. Lázaro, M. Chang, W. Tang et al., “Hepatitis C virus replication in transfected and serum-infected cultured human fetal hepatocytes,” American Journal of Pathology, vol. 170, no. 2, pp. 478–489, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  13. T. Marcello, A. Grakoui, G. Barba-Spaeth et al., “Interferons α and λ inhibit hepatitis C virus replication with distinct signal transduction and gene regulation kinetics,” Gastroenterology, vol. 131, no. 6, pp. 1887–1898, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  14. M. D. Robek, B. S. Boyd, and F. V. Chisari, “Lambda interferon inhibits hepatitis B and C virus replication,” Journal of Virology, vol. 79, no. 6, pp. 3851–3854, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  15. W. Hou, X. Wang, L. Ye et al., “Lambda interferon inhibits human immunodeficiency virus type 1 infection of macrophages,” Journal of Virology, vol. 83, no. 8, pp. 3837–3842, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  16. J. Li, S. Hu, L. Zhou et al., “Interferon lambda inhibits herpes simplex virus type I infection of human astrocytes and neurons,” Glia, vol. 59, no. 1, pp. 58–67, 2011. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  17. A. Meager, K. Visvalingam, P. Dilger, D. Bryan, and M. Wadhwa, “Biological activity of interleukins-28 and -29: comparison with type I interferons,” Cytokine, vol. 31, no. 2, pp. 109–118, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  18. S. G. Maher, F. Sheikh, A. J. Scarzello et al., “IFNα and IFNλ differ in their antiproliferative effects and duration of JAK/STAT signaling activity,” Cancer Biology and Therapy, vol. 7, no. 7, pp. 1109–1115, 2008. View at Google Scholar · View at Scopus
  19. C. A. Biron, “Interferons α and β as immune regulators—a new look,” Immunity, vol. 14, no. 6, pp. 661–664, 2001. View at Publisher · View at Google Scholar · View at Scopus
  20. A. Le Bon and D. F. Tough, “Links between innate and adaptive immunity via type I interferon,” Current Opinion in Immunology, vol. 14, no. 4, pp. 432–436, 2002. View at Publisher · View at Google Scholar · View at Scopus
  21. W. J. Jordan, J. Eskdale, M. Boniotto, M. Rodia, D. Kellner, and G. Gallagher, “Modulation of the human cytokine response by interferon lambda-1 (IFN-λ1/IL-29),” Genes and Immunity, vol. 8, no. 1, pp. 13–20, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  22. N. J. Megjugorac, G. E. Gallagher, and G. Gallagher, “Modulation of human plasmacytoid DC function by IFN-λ1 (IL-29),” Journal of Leukocyte Biology, vol. 86, no. 6, pp. 1359–1363, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  23. J. Dai, N. J. Megjugorac, G. E. Gallagher, R. Y. L. Yu, and G. Gallagher, “IFN-λ1 (IL-29) inhibits GATA3 expression and suppresses Th2 responses in human naive and memory T cells,” Blood, vol. 113, no. 23, pp. 5829–5838, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  24. W. J. Jordan, J. Eskdale, S. Srinivas et al., “Human interferon lambda-1 (IFN-λ1/IL-29) modulates the Th1/Th2 response,” Genes and Immunity, vol. 8, no. 3, pp. 254–261, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  25. S. Srinivas, J. Dai, J. Eskdale, G. E. Gallagher, N. J. Megjugorac, and G. Gallagher, “Interferon-λ1 (interleukin-29) preferentially down-regulates interleukin-13 over other T helper type 2 cytokine responses in vitro,” Immunology, vol. 125, no. 4, pp. 492–502, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  26. D. M. A. Bullens, A. Decraene, E. Dilissen et al., “Type III IFN-λ mRNA expression in sputum of adult and school-aged asthmatics,” Clinical and Experimental Allergy, vol. 38, no. 9, pp. 1459–1467, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  27. S. L. Johnston, “Innate immunity in the pathogenesis of virus-induced asthma exacerbations,” Proceedings of the American Thoracic Society, vol. 4, no. 3, pp. 267–270, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  28. E. M. Coccia, M. Severa, E. Giacomini et al., “Viral infection and toll-like receptor agonists induce a differential expression of type I and λ interferons in humans plasmacytoid and monocyte-derived dendritic cells,” European Journal of Immunology, vol. 34, no. 3, pp. 796–805, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  29. F. J. D. Mennechet and G. Uzé, “Interferon-λ-treated dendritic cells specifically induce proliferation of FOXP3-expressing suppressor T cells,” Blood, vol. 107, no. 11, pp. 4417–4423, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  30. M. P. Morrow, P. Pankhong, D. J. Laddy et al., “Comparative ability of IL-12 and IL-28B to regulate Treg populations and enhance adaptive cellular immunity,” Blood, vol. 113, no. 23, pp. 5868–5877, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  31. S. D. Der, A. Zhou, B. R. G. Williams, and R. H. Silverman, “Identification of genes differentially regulated by interferon α, β, or γ using oligonucleotide arrays,” Proceedings of the National Academy of Sciences of the United States of America, vol. 95, no. 26, pp. 15623–15628, 1998. View at Publisher · View at Google Scholar · View at Scopus
  32. S. E. Doyle, H. Schreckhise, K. Khuu-Duong et al., “Interleukin-29 uses a type 1 interferon-like program to promote antiviral responses in human hepatocytes,” Hepatology, vol. 44, no. 4, pp. 896–906, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  33. M. J. Clemens, “Interferons and apoptosis,” Journal of Interferon and Cytokine Research, vol. 23, no. 6, pp. 277–292, 2003. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  34. D. V. Kalvakolanu, “The GRIMs: a new interface between cell death regulation and interferon/retinoid induced growth suppression,” Cytokine and Growth Factor Reviews, vol. 15, no. 2-3, pp. 169–194, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  35. L. Dumoutier, A. Tounsi, T. Michiels, C. Sommereyns, S. V. Kotenko, and J. C. Renauld, “Role of the interleukin (IL)-28 receptor tyrosine residues for antiviral and antiproliferative activity of IL-29/interferon-λ1. Similarities with type 1 interferon signaling,” Journal of Biological Chemistry, vol. 279, no. 31, pp. 32269–32274, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  36. S. Brand, F. Beigel, T. Olszak et al., “IL-28A and IL-29 mediate antiproliferative and antiviral signals in intestinal epithelial cells and murine CMV infection increases colonic IL-28A expression,” American Journal of Physiology, vol. 289, no. 5, pp. G960–G968, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  37. K. Zitzmann, S. Brand, S. Baehs et al., “Novel interferon-λs induce antiproliferative effects in neuroendocrine tumor cells,” Biochemical and Biophysical Research Communications, vol. 344, no. 4, pp. 1334–1341, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  38. W. Li, A. Lewis-Antes, J. Huang, M. Balan, and S. V. Kotenko, “Regulation of apoptosis by type III interferons,” Cell Proliferation, vol. 41, no. 6, pp. 960–979, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  39. A. J. Novak, D. M. Grote, S. C. Ziesmer, V. Rajkumar, S. E. Doyle, and S. M. Ansell, “A role for IFN-λ1 in multiple myeloma B cell growth,” Leukemia, vol. 22, no. 12, pp. 2240–2246, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  40. C. Sommereyns, S. Paul, P. Staeheli, and T. Michiels, “IFN-lambda (IFN-λ) is expressed in a tissue-dependent fashion and primarily acts on epithelial cells in vivo,” PLoS Pathogens, vol. 4, no. 3, Article ID e1000017, 2008. View at Publisher · View at Google Scholar · View at PubMed
  41. J. Pott, T. Mahlakõiv, M. Mordstein et al., “IFN-λ determines the intestinal epithelial antiviral host defense,” Proceedings of the National Academy of Sciences of the United States of America, vol. 108, no. 19, pp. 7944–7949, 2011. View at Publisher · View at Google Scholar · View at PubMed
  42. N. A. Jewell, T. Cline, S. E. Mertz et al., “Lambda interferon is the predominant interferon induced by influenza A virus infection in vivo,” Journal of Virology, vol. 84, no. 21, pp. 11515–11522, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  43. J. E. Pulverer, U. Rand, S. Lienenklaus et al., “Temporal and spatial resolution of type I and III interferon responses in vivo,” Journal of Virology, vol. 84, no. 17, pp. 8626–8638, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  44. O. Koltsida, M. Hausding, A. Stavropoulos et al., “IL-28A (IFN-λ2) modulates lung DC function to promote Th1 immune skewing and suppress allergic airway disease,” EMBO Molecular Medicine, vol. 3, no. 6, pp. 348–361, 2011. View at Publisher · View at Google Scholar · View at PubMed
  45. W. Abushahba, M. Balan, I. Castaneda et al., “Antitumor activity of type I and type III interferons in BNL hepatoma model,” Cancer Immunology, Immunotherapy, vol. 59, no. 7, pp. 1059–1071, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  46. K. Witte, G. Gruetz, H. D. Volk et al., “Despite IFN-receptor expression, blood immune cells, but not keratinocytes or melanocytes, have an impaired response to type III interferons: implications for therapeutic applications of these cytokines,” Genes and Immunity, vol. 10, no. 8, pp. 702–714, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  47. K. Wolk, K. Witte, E. Witte et al., “Maturing dendritic cells are an important source of IL-29 and IL-20 that may cooperatively increase the innate immunity of keratinocytes,” Journal of Leukocyte Biology, vol. 83, no. 5, pp. 1181–1193, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  48. C. Dellgren, H. H. Gad, O. J. Hamming, J. Melchjorsen, and R. Hartmann, “Human interferon-λ3 is a potent member of the type III interferon family,” Genes and Immunity, vol. 10, no. 2, pp. 125–131, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  49. C. Thomas, I. Moraga, D. Levin et al., “Structural linkage between ligand discrimination and receptor activation by type I interferons,” Cell, vol. 146, no. 4, pp. 621–632, 2011. View at Publisher · View at Google Scholar · View at PubMed
  50. M. Mordstein, E. Neugebauer, V. Ditt et al., “Lambda interferon renders epithelial cells of the respiratory and gastrointestinal tracts resistant to viral infections,” Journal of Virology, vol. 84, no. 11, pp. 5670–5677, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  51. A. J. Muir, M. L. Shiffman, A. Zaman et al., “Phase 1b study of pegylated interferon lambda 1 with or without ribavirin in patients with chronic genotype 1 hepatitis C virus infection,” Hepatology, vol. 52, no. 3, pp. 822–832, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  52. C. Kelly, P. Klenerman, and E. Barnes, “Interferon lambdas: the next cytokine storm,” Gut, vol. 60, no. 9, pp. 1284–1293, 2011. View at Publisher · View at Google Scholar · View at PubMed
  53. D. Ge, J. Fellay, A. J. Thompson et al., “Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance,” Nature, vol. 461, no. 7262, pp. 399–401, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  54. D. Labie and H. Gilgenkrantz, “IL28 (interferon lambda3) gene polymorphisms and response to IFN-alpha treatment in patients infected with hepatitis virus C,” Médecine Sciences, vol. 26, no. 3, pp. 225–226, 2010. View at Google Scholar · View at Scopus
  55. A. Mangia, A. J. Thompson, R. Santoro et al., “An IL28B polymorphism determines treatment response of hepatitis C virus genotype 2 or 3 patients who do not achieve a rapid virologic response,” Gastroenterology, vol. 139, no. 3, pp. 821–e1, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  56. J. J. McCarthy, J. H. Li, A. Thompson et al., “Replicated association between an IL28B gene variant and a sustained response to pegylated interferon and ribavirin,” Gastroenterology, vol. 138, no. 7, pp. 2307–2314, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  57. M. A. Montes-Cano, J. R. García-Lozano, C. Abad-Molina et al., “Interleukin-28B genetic variants and hepatitis virus infection by different viral genotypes,” Hepatology, vol. 52, no. 1, pp. 33–37, 2010. View at Publisher · View at Google Scholar · View at PubMed
  58. T. L. Mosbruger, P. Duggal, J. J. Goedert et al., “Large-scale candidate gene analysis of spontaneous clearance of hepatitis C virus,” Journal of Infectious Diseases, vol. 201, no. 9, pp. 1371–1380, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  59. A. Rauch, Z. Kutalik, P. Descombes et al., “Genetic variation in IL28B is associated with chronic hepatitis C and treatment failure: a genome-wide association study,” Gastroenterology, vol. 138, no. 4, pp. 1338–1345, 2010. View at Publisher · View at Google Scholar · View at PubMed
  60. V. Suppiah, M. Moldovan, G. Ahlenstiel et al., “IL28B is associated with response to chronic hepatitis C interferon-α and ribavirin therapy,” Nature Genetics, vol. 41, no. 10, pp. 1100–1104, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  61. Y. Tanaka, N. Nishida, M. Sugiyama et al., “Genome-wide association of IL28B with response to pegylated interferon-α and ribavirin therapy for chronic hepatitis C,” Nature Genetics, vol. 41, no. 10, pp. 1105–1109, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  62. A. Lasfar, W. Abushahba, A. de la Torre, I. Castaneda, S. V. Kotenko, and K. Reuhl, “IFN therapy in TIB75 HCC model: combination of IFN-lambda and IFN-alpha induces complete remission,” Hepathology, vol. 48, no. 4, supplement, #191, 2008. View at Google Scholar
  63. J. M. Kirkwood, J. Ibrahim, D. H. Lawson et al., “High-dose interferon alfa-2b does not diminish antibody response to GM2 vaccination in patients with resected melanoma: results of the multicenter eastern cooperative oncology group phase II trial E2696,” Journal of Clinical Oncology, vol. 19, no. 5, pp. 1430–1436, 2001. View at Google Scholar · View at Scopus
  64. J. M. Kirkwood, M. H. Strawderman, M. S. Ernstoff, T. J. Smith, E. C. Borden, and R. H. Blum, “Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group trial EST 1684,” Journal of Clinical Oncology, vol. 14, no. 1, pp. 7–17, 1996. View at Google Scholar · View at Scopus
  65. S. Moschos, S. Varanasi, and J. M. Kirkwood, “Interferons in the treatment of solid tumors,” Cancer Treatment and Research, vol. 126, pp. 207–241, 2005. View at Google Scholar · View at Scopus
  66. N. Cascinelli, F. Belli, R. M. MacKie, M. Santinami, R. Bufalino, and A. Morabito, “Effect of long-term adjuvant therapy with interferon alpha-2a in patients with regional node metastases from cutaneous melanoma: a randomised trial,” Lancet, vol. 358, no. 9285, pp. 866–869, 2001. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  67. U. R. Kleeberg, S. Suciu, E. B. Bröcker et al., “Final results of the EORTC 18871/DKG 80-1 randomised phase III trial: rIFN-α2b versus rIFN-γ versus ISCADOR M versus observation after surgery in melanoma patients with either high-risk primary (thickness >3 mm) or regional lymph node metastasis,” European Journal of Cancer, vol. 40, no. 3, pp. 390–402, 2004. View at Publisher · View at Google Scholar
  68. A. Sato, M. Ohtsuki, M. Hata, E. Kobayashi, and T. Murakami, “Antitumor activity of IFN-λ in murine tumor models,” Journal of Immunology, vol. 176, no. 12, pp. 7686–7694, 2006. View at Google Scholar · View at Scopus
  69. M. Numasaki, M. Tagawa, F. Iwata et al., “IL-28 elicits antitumor responses against murine fibrosarcoma,” Journal of Immunology, vol. 178, no. 8, pp. 5086–5098, 2007. View at Google Scholar · View at Scopus
  70. P. A. Farazi and R. A. DePinho, “Hepatocellular carcinoma pathogenesis: from genes to environment,” Nature Reviews Cancer, vol. 6, no. 9, pp. 674–687, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  71. W. Y. Lau and E. C. H. Lai, “Hepatocellular carcinoma: current management and recent advances,” Hepatobiliary and Pancreatic Diseases International, vol. 7, no. 3, pp. 237–257, 2008. View at Google Scholar · View at Scopus
  72. M. Sherman, “Hepatocellular carcinoma: epidemiology, risk factors, and screening,” Seminars in Liver Disease, vol. 25, no. 2, pp. 143–154, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  73. V. Mazzaferro, Y. S. Chun, R. T. P. Poon et al., “Liver transplantation for hepatocellular carcinoma,” Annals of Surgical Oncology, vol. 15, no. 4, pp. 1001–1007, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  74. V. Mazzaferro, J. M. Llovet, R. Miceli et al., “Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: a retrospective, exploratory analysis,” The Lancet Oncology, vol. 10, no. 1, pp. 35–43, 2009. View at Publisher · View at Google Scholar · View at Scopus
  75. A. Taketomi, Y. Soejima, T. Yoshizumi, H. Uchiyama, Y. I. Yamashita, and Y. Maehara, “Liver transplantation for hepatocellular carcinoma,” Journal of Hepato-Biliary-Pancreatic Surgery, vol. 15, no. 2, pp. 124–130, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  76. C. S. Georgiades, K. Hong, and J. F. Geschwind, “Radiofrequency ablation and chemoembolization for hepatocellular carcinoma,” Cancer Journal, vol. 14, no. 2, pp. 117–122, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  77. A. M. Di Bisceglie, R. L. Carithers, and G. J. Gores, “Hepatocellular carcinoma,” Hepatology, vol. 28, no. 4 I, pp. 1161–1165, 1998. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  78. H. Nagai and Y. Sumino, “Therapeutic strategy of advanced hepatocellular carcinoma by using combined intra-arterial chemotherapy,” Recent Patents on Anti-Cancer Drug Discovery, vol. 3, no. 3, pp. 220–226, 2008. View at Publisher · View at Google Scholar · View at Scopus
  79. H. B. El-Serag, “Hepatocellular carcinoma: an epidemiologic view,” Journal of Clinical Gastroenterology, vol. 35, no. 5, pp. S72–S78, 2002. View at Publisher · View at Google Scholar · View at Scopus
  80. L. Wang, W. Z. Wu, H. C. Sun et al., “Mechanism of interferon alpha on inhibition of metastasis and angiogenesis of hepatocellular carcinoma after curative resection in nude mice,” Journal of Gastrointestinal Surgery, vol. 7, no. 5, pp. 587–594, 2003. View at Publisher · View at Google Scholar · View at Scopus
  81. G. Fattovich, G. Giustina, J. Sanchez-Tapias et al., “Delayed clearance of serum HBsAG in compensated cirrhosis B: relation to interferon alpha therapy and disease prognosis,” The American Journal of Gastroenterology, vol. 93, no. 6, pp. 896–900, 1998. View at Publisher · View at Google Scholar · View at PubMed
  82. S. M. Lin, M. L. Yu, C. M. Lee et al., “Interferon therapy in HBeAg positive chronic hepatitis reduces progression to cirrhosis and hepatocellular carcinoma,” Journal of Hepatology, vol. 46, no. 1, pp. 45–52, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  83. M. Omata, H. Yoshida, and Y. Shiratori, “Prevention of hepatocellular carcinoma and its recurrence in chronic hepatitis C patients by interferon therapy,” Clinical Gastroenterology and Hepatology, vol. 3, no. 2, pp. S141–S143, 2005. View at Publisher · View at Google Scholar · View at Scopus
  84. M. L. Yu, S. M. Lin, W. L. Chuang et al., “A sustained virological response to interferon or interferon/ribavirin reduces hepatocellular carcinoma and improves survival in chronic hepatitis C: a nationwide, multicentre study in Taiwan,” Antiviral Therapy, vol. 11, no. 8, pp. 985–994, 2006. View at Google Scholar · View at Scopus
  85. J. M. Llovet, M. Sala, L. Castells et al., “Randomized controlled trial of interferon treatment for advanced hepatocellular carcinoma,” Hepatology, vol. 31, no. 1, pp. 54–58, 2000. View at Google Scholar · View at Scopus
  86. C. M. Lo, C. L. Liu, S. C. Chan et al., “A randomized, controlled trial of postoperative adjuvant interferon therapy after resection of hepatocellular carcinoma,” Annals of Surgery, vol. 245, no. 6, pp. 831–842, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  87. K. Ueshima, M. Kudo, T. Nagai et al., “Combination therapy with S-1 and pegylated interferon alpha for advanced hepatocellular carcinoma,” Oncology, vol. 75, no. 1, pp. 106–113, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  88. Y. A. Sidky and E. C. Borden, “Inhibition of angiogenesis by interfersons: effects on tumor- and lymphocyte-induced vascular responses,” Cancer Research, vol. 47, no. 19, pp. 5155–5161, 1987. View at Google Scholar · View at Scopus
  89. C. P. N. Dinney, D. R. Bielenberg, P. Perrotte et al., “Inhibition of basic fibroblast growth factor expression, angiogenesis, and growth of human bladder carcinoma in mice by systemic interferon-α administration,” Cancer Research, vol. 58, no. 4, pp. 808–814, 1998. View at Google Scholar · View at Scopus
  90. Y. Dong, W. M. Rohn, and E. N. Benveniste, “IFN-γ regulation of the type IV class II transactivator promoter in astrocytes,” Journal of Immunology, vol. 162, no. 8, pp. 4731–4739, 1999. View at Google Scholar · View at Scopus
  91. I. Gresser, “Antitumour effects of interferons: past, present and future,” British Journal of Haematology, Supplement, vol. 79, no. 1, pp. 1–5, 1991. View at Google Scholar · View at Scopus
  92. I. Gresser, T. Kaido, C. Maury, D. Woodrow, J. Moss, and F. Belardelli, “Interaction of IFN α/β with host cells essential to the early inhibition of friend erythroleukemia visceral metastases in mice,” International Journal of Cancer, vol. 57, no. 4, pp. 604–611, 1994. View at Publisher · View at Google Scholar · View at Scopus
  93. T. Kaido, C. Maury, V. Schirrmacher, and I. Gresser, “Successful immunotherapy of the highly metastatic murine ESb lymphoma with sensitized CD8+ T cells and IFN-α/β,” International Journal of Cancer, vol. 57, no. 4, pp. 538–543, 1994. View at Publisher · View at Google Scholar · View at Scopus
  94. T. J. Kaido, C. Maury, and I. Gresser, “Host CD4+ T lymphocytes are required for the synergistic action of interferonα/β and adoptively transferred immune cells in the inhibition of visceral ESb metastases,” Cancer Research, vol. 55, no. 24, pp. 6133–6139, 1995. View at Google Scholar · View at Scopus
  95. D. Javelaud, V. I. Alexaki, and A. Mauviel, “Transforming growth factor-β in cutaneous melanoma,” Pigment Cell & Melanoma Research, vol. 21, no. 2, pp. 123–132, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  96. A. Lasfar and K. A. Cohen-Solal, “Resistance to transforming growth factor β-mediated tumor suppression in melanoma: are multiple mechanisms in place?” Carcinogenesis, vol. 31, no. 10, pp. 1710–1717, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus